Immunogenicity of pembrolizumab (pembro) in patients (pts) with advanced melanoma (MEL) and non-small cell lung cancer (NSCLC): Pooled results from KEYNOTE-001, 002, 006, and 010
| Autor: | Rik de Greef, Tomoko Freshwater, Anna Georgieva Kondic, Eric Mangin, Marianne van Vugt, Frank van Aarle |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Cancer Research
biology business.industry medicine.drug_class Immunogenicity food and beverages non-small cell lung cancer (NSCLC) Pembrolizumab Monoclonal antibody medicine.disease 030226 pharmacology & pharmacy 03 medical and health sciences 0302 clinical medicine Oncology 030220 oncology & carcinogenesis Cancer research biology.protein Medicine In patient Antibody business Advanced melanoma |
| Zdroj: | Journal of Clinical Oncology. 34:3063-3063 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2016.34.15_suppl.3063 |
| Popis: | 3063Background: Monoclonal antibodies (mAb) can evoke immunogenicity, leading to production of antidrug antibodies (ADA). Pembro, a humanized mAb against PD-1, has demonstrated efficacy in NSCLC an... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|